Low Serum Vitamin B-12 Concentrations Are Prevalent in a Cohort of Pregnant Canadian Women

J Nutr. 2016 May;146(5):1035-42. doi: 10.3945/jn.115.226845. Epub 2016 Apr 13.

Abstract

Background: Among Canadian women of reproductive age, 5% and 20% have serum vitamin B-12 concentrations indicative of deficiency (<148 pmol/L) and marginal status (148-220 pmol/L), respectively. Given the association between suboptimal vitamin B-12 and adverse pregnancy outcomes, an understanding of vitamin B-12 status during pregnancy, and factors that influence it, is required.

Objective: This prospective analysis from the PREFORM (PREnatal FOlic acid exposuRe on DNA Methylation in the newborn infant) study investigated 1) vitamin B-12 status in a cohort of Canadian pregnant women and their newborns, 2) the association of maternal dietary vitamin B-12 intake with maternal and cord blood concentrations of vitamin B-12 and its biomarkers, and 3) the association of fetal genetic polymorphisms with cord blood concentrations of vitamin B-12 and its biomarkers.

Methods: In pregnant Canadian women (n = 368; mean ± SD age: 32 ± 5 y), vitamin B-12 intakes were assessed in early (0-16 wk) and mid- to late (23-37 wk) pregnancy. Serum vitamin B-12 and plasma total homocysteine (tHcy) and methylmalonic acid (MMA) in maternal blood at 12-16 wk of pregnancy and at delivery (28-42 wk) and in cord blood were measured and compared by using regression analyses. The associations of 28 fetal genetic variants in vitamin B-12 metabolism and cord blood vitamin B-12, tHcy, and MMA concentrations were assessed by using regression analysis, with adjustment for multiple testing.

Results: A total of 17% and 38% of women had deficient and 35% and 43% had marginal serum vitamin B-12 concentrations at 12-16 wk of pregnancy and at delivery, respectively. Only 1.9-5.3% had elevated MMA (>271 nmol/L), and no women had elevated tHcy (>13 μmol/L). Maternal dietary vitamin B-12 intake during pregnancy was either weakly associated or not associated with maternal and cord blood vitamin B-12 (r(2) = 0.17-0.24, P < 0.0008), tHcy (P = NS) and MMA (r(2) = 0.05-0.11, P < 0.001). Fetal genetic polymorphisms were not associated with cord blood concentrations of vitamin B-12 and its biomarkers.

Conclusions: Deficient and marginal serum vitamin B-12 concentrations are prevalent in Canadian pregnant women with the use of traditional cutoffs, despite supplement use. Given the growing interest among women to adhere to a vegetarian diet that may be lower in vitamin B-12, and vitamin B-12's importance in pregnancy, the functional ramifications of these observations need to be elucidated. This trial was registered at clinicaltrials.gov as NCT02244684.

Keywords: fetal genotype; homocysteine; maternal diet; methylmalonic acid; pregnancy; vitamin B-12.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Canada / epidemiology
  • DNA Methylation
  • Diet
  • Dietary Supplements
  • Female
  • Fetal Blood / metabolism
  • Fetus
  • Folic Acid / blood
  • Homocysteine / blood
  • Humans
  • Infant, Newborn
  • Methylmalonic Acid / blood
  • Polymorphism, Genetic
  • Pregnancy
  • Pregnancy Complications / epidemiology*
  • Prevalence
  • Prospective Studies
  • Vitamin B 12 / administration & dosage
  • Vitamin B 12 / blood*
  • Vitamin B 12 Deficiency / epidemiology*
  • Vitamin B Complex / administration & dosage
  • Vitamin B Complex / blood

Substances

  • Homocysteine
  • Vitamin B Complex
  • Methylmalonic Acid
  • Folic Acid
  • Vitamin B 12

Associated data

  • ClinicalTrials.gov/NCT02244684

Grants and funding